Cargando…
Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment outcome, especially in patients that are ineligible for intensive chemotherapy. Immunotherapy, comprising checkpoint inhibition, T-cell engaging antibody constructs, and cellular therapies, has dramatically im...
Autores principales: | Rausch, Johanna, Ullrich, Evelyn, Kühn, Michael W.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556528/ https://www.ncbi.nlm.nih.gov/pubmed/37809078 http://dx.doi.org/10.3389/fimmu.2023.1269012 |
Ejemplares similares
-
The potential role of the thymus in immunotherapies for acute myeloid leukemia
por: Hino, Christopher, et al.
Publicado: (2023) -
Dendritic Cell-Based Immunotherapy for Myeloid Leukemias
por: Schürch, Christian M., et al.
Publicado: (2013) -
The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
por: Parisi, Sarah, et al.
Publicado: (2017) -
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
por: Le Roy, Aude, et al.
Publicado: (2018) -
Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)